BYSI - BeyondSpring Inc
BeyondSpring Inc Logo

BYSI - BeyondSpring Inc

https://beyondspringpharma.com
Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

BeyondSpring Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology cancer therapies. The company is headquartered in New York, New York.

52W High
$3.44
52W Low
$0.98
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
0.22
Valuation
Attractive
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
10.54
EV/EBITDA (<8 favorable)
0.05
EV/Revenue (<3 favorable)
26.53
P/S (TTM) (<3 favorable)
31.22
P/B (<3 favorable)
5.38
Ownership
Retail‑heavy
Source: Overview
Insiders (1–5% typical)
15.26%
Institutions (25–75% balanced)
14.67%
Shares Outstanding
40,332,300
Float
30,288,800
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
1,876,000
Gross Profit (TTM)
1,351,000
EPS (TTM)
-0.20
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
-3.11%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
0.14
Momentum
Bearish momentum
Value
-0.0322
Previous
-0.0292
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025